Fenbendazole 222 mg — 120 Capsules (99% Purity)

Fenbendazole 222mg Capsules — Standard Protocol Dose

Fenbendazole is a broad-spectrum benzimidazole anthelmintic with a long-established record in veterinary medicine and a rapidly growing body of human research. Originally developed and approved for use in dogs, cats, horses, and livestock, fenbendazole has attracted significant scientific interest over the past decade for its potential applications in human health — particularly oncology research. Each capsule in this product contains 222 mg of pharmaceutical-grade fenbendazole powder at 99.36% purity. The 222 mg dose corresponds precisely to the widely-referenced human off-label research protocol, making this the standard protocol dose for individuals exploring fenbendazole for investigational purposes.

Mechanism of Action

Fenbendazole exerts its effects through multiple complementary pathways, which has driven interest in its potential beyond veterinary antiparasitic use:

• Microtubule disruption via β-tubulin binding: Fenbendazole binds selectively to β-tubulin and disrupts microtubule polymerization — preventing formation of the mitotic spindle required for cell division. This is the same fundamental mechanism employed by several established chemotherapy agents; vinca alkaloids inhibit tubulin polymerization, while taxanes stabilize microtubules — both ultimately disrupting mitosis.
• Glucose uptake inhibition: Fenbendazole moderately interferes with GLUT transporter function, reducing glucose uptake in both parasites and certain cancer cell lines. Cancer cells rely heavily on aerobic glycolysis (the Warburg effect) and are particularly sensitive to glucose deprivation.
• p53 stabilization: Research has demonstrated that fenbendazole can stabilize and activate p53 — a critical tumor suppressor protein that triggers apoptosis in damaged or abnormal cells.
• Proteasomal interference: Fenbendazole has been shown to interfere with proteasomal function, disrupting the cellular protein degradation machinery that cancer cells depend on for survival and proliferation.

Anticancer Research

Interest in fenbendazole as a potential anticancer compound accelerated dramatically following the public account of Joe Tippens, a US patient diagnosed with stage 4 small cell lung cancer in 2016. Given a terminal prognosis, Tippens began a self-administered fenbendazole protocol alongside standard treatment. By 2018, his cancer was reportedly in complete remission, an outcome he attributed in part to fenbendazole. His story spread widely online and in South Korean media, spurring a wave of patient interest and prompting formal scientific investigation.

Peer-reviewed research on fenbendazole's anticancer properties includes:

• Dogra et al., 2018 (Scientific Reports): Demonstrated that fenbendazole causes mitotic arrest and apoptosis in human non-small cell lung cancer (NSCLC) cells.
• Florio et al., 2019: Investigated fenbendazole's effects in glioblastoma (GBM) — one of the most treatment-resistant brain cancers.
• Song et al., 2022: Contributed to the growing body of work examining fenbendazole in combination with other agents.
• Additional published studies have explored activity in colorectal cancer, ovarian cancer, and prostate cancer cell lines and animal models.

Fenbendazole is being actively studied as a repurposed drug — a compound already known to be safe in animals and with a well-characterized toxicity profile, evaluated for new indications alongside standard oncology treatments. It is not an approved cancer treatment in humans, and research is ongoing.

Veterinary Uses

Fenbendazole remains one of the most widely used and trusted broad-spectrum dewormers in veterinary practice worldwide. It is effective against:

• Dogs: Roundworms (Toxocara canis), hookworms, whipworms (Trichuris vulpis), certain tapeworms (Taenia spp.), giardia, and lungworms.
• Cats: Roundworms (Toxocara cati), hookworms, giardia.
• Horses: Strongyles, ascarids, pinworms, and other equine intestinal parasites.
• Livestock and exotic animals: Widely used across species for gastrointestinal nematode infections.

Human Research Dosage Protocols

The most widely cited off-label human research protocol is the "Tippens Protocol":

• Dose: 222 mg fenbendazole per day (1 capsule of this product)
• Schedule: 3 days on, 4 days off (cycling weekly)
• Context: Often used alongside vitamin E succinate and bioavailable curcumin in the full Tippens stack, though fenbendazole is the central compound

The 222 mg dose is substantially lower than standard veterinary antiparasitic doses scaled for human body weight, and is thought to be well below levels associated with toxicity. Higher-dose protocols (e.g., 444 mg/day) are also being explored in some research contexts.

Always consult a qualified healthcare provider before beginning any off-label protocol. This product is not intended to diagnose, treat, cure, or prevent any disease.

Product Details

Safety & Side Effects

Fenbendazole has a well-established safety profile developed over decades of veterinary use. In human research contexts, it is generally considered well-tolerated at the doses used in common off-label protocols:

• Mild gastrointestinal effects (nausea, loose stools, diarrhea) may occur, particularly when starting use.
• Elevated liver enzymes (transaminases) have been reported with prolonged continuous use. Liver function monitoring is recommended for anyone using fenbendazole on an extended basis.
• The 3-days-on / 4-days-off cycling protocol is in part designed to reduce hepatic burden.
• Not recommended for use during pregnancy or breastfeeding without medical supervision.
• If you are on prescription medications or undergoing cancer treatment, consult your oncologist or physician before use.

Frequently Asked Questions

What is fenbendazole?

Fenbendazole is a broad-spectrum benzimidazole anthelmintic — a class of compound originally developed for veterinary use to treat parasitic worm infections in animals. It has a decades-long safety record in dogs, cats, horses, and livestock. In recent years, it has attracted substantial scientific interest for potential applications in human oncology research.

What is the Tippens Protocol?

The Tippens Protocol refers to the off-label fenbendazole regimen popularized by Joe Tippens. The core protocol involves 222 mg of fenbendazole daily for 3 consecutive days, followed by 4 days off, repeated weekly. This is often combined with vitamin E succinate and curcumin. The 222 mg per capsule dose of this product is specifically sized to match this protocol.

How does fenbendazole work against cancer cells?

Research suggests fenbendazole acts on cancer cells through several mechanisms: disrupting microtubule polymerization by binding to β-tubulin, moderately inhibiting glucose uptake, stabilizing p53, and interfering with proteasomal function. This multi-pathway activity is one reason fenbendazole has attracted significant research interest.

Is fenbendazole safe for humans?

Fenbendazole has an extensive veterinary safety record and is generally considered well-tolerated at the doses used in human research protocols. Mild side effects such as nausea or loose stools may occur. Elevated liver enzymes have been observed with prolonged use, so liver function monitoring is recommended for extended protocols. Fenbendazole is not FDA-approved for human use.

Can I buy fenbendazole without a prescription?

Yes, fenbendazole is available over the counter and does not require a prescription. Our 222 mg capsules ship directly from Florida with free delivery on every order.